Heterogeneity in tuberculosis pathology, microenvironments and therapeutic responses

Immunological Reviews

Volumn 264, Issue 1, 2015, Pages 288-307

  Lenaerts, Anne ^a   Barry, Clifton E ^b   Dartois, Véronique ^c  

^a Department of Ecosystem Science and Sustainability   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

Animal models; Biomarkers; Immunopathology; Lesion dynamics; Tuberculosis

Indexed keywords

LINEZOLID; TUBERCULOSTATIC AGENT;

ARTICLE; BACTERIAL LOAD; COMPUTER ASSISTED TOMOGRAPHY; HOST PATHOGEN INTERACTION; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOLOGY; LATENT TUBERCULOSIS; LUNG BIOPSY; LUNG GRANULOMA; MICROENVIRONMENT; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RELATIVE DENSITY; TREATMENT RESPONSE; TUBERCULOSIS; ANIMAL; DISEASE MODEL; GRANULOMA; IMMUNOLOGY; MYCOBACTERIUM TUBERCULOSIS; PATHOLOGY; TREATMENT OUTCOME;

ANIMALS; ANTITUBERCULAR AGENTS; DISEASE MODELS, ANIMAL; GRANULOMA; HOST-PATHOGEN INTERACTIONS; HUMANS; LATENT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 84923172431     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/imr.12252     Document Type: Article

References (143)

1. Barnes DS. The Making of a Social Disease - Tuberculosis in Nineteenth-Century France. Berkeley, Los Angeles, London: University of California Press, 1995.
2. Canetti G. The Tubercle Bacillus. New York: Springer Publishing COmpany, 1955.
3. Dannenberg AM, Jr. Pathogenesis of Human Pulmonary Tuberculosis. Washington, DC: ASM Press, 2006.
4. Via LE, et al. Infection dynamics and response to chemotherapy in a Rabbit model of tuberculosis using (18F)2-fluoro-deoxy-D-glucose positron emission tomography and computed tomography. Antimicrob Agents Chemother 2012;56:4391-4402.
5. Via LE, et al. Differential virulence and disease progression following Mycobacterium tuberculosis complex infection of the common marmoset (Callithrix jacchus). Infect Immun 2013;81:2909-2919.
6. Bagci U, et al. A computational pipeline for quantification of pulmonary infections in small animal models using serial PET-CT imaging. EJNMMI Res 2013;3:55.
7. Murawski AM, et al. Imaging the evolution of reactivation pulmonary tuberculosis in mice using 18F-FDG PET. J Nucl Med 2014. doi: 10.2967/jnumed.114.144634.
8. Esmail H, et al. The ongoing challenge of latent tuberculosis. Philos Trans R Soc Lond B Biol Sci 2014;369:20130437.
9. Lawn SD, Wood R, Wilkinson RJ. Changing concepts of "latent tuberculosis infection" in patients living with HIV infection. Clin Dev Immunol 2011;2011. doi: 10.1155/2011/980594.
10. Barry CER, et al. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol 2009;7:845-855.
11. Young DB, Gideon HP, Wilkinson RJ. Eliminating latent tuberculosis. Trends Microbiol 2009;17:183-188.
12. Capuano SV 3rd, et al. Experimental Mycobacterium tuberculosis infection of cynomolgus macaques closely resembles the various manifestations of human M. tuberculosis infection. Infect Immun 2003;71:5831-5844.
13. Lin PL, et al. Quantitative comparison of active and latent tuberculosis in the cynomolgus macaque model. Infect Immun 2009;77:4631-4642.
14. Berry MP, et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 2010;466:973-977.
15. Bloom CI, et al. Transcriptional blood signatures distinguish pulmonary tuberculosis, pulmonary sarcoidosis, pneumonias and lung cancers. PLoS ONE 2013;8:e70630.
16. Lee M, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med 2012;367:1508-1518.
17. Coleman MT, et al. PET/CT monitoring demonstrates a therapeutic response to oxazolidinones in Mycobacterium tuberculosis infected macaques and humans. Sci Transl Med 2014;6:265ra167.
18. Aber VR, Nunn AJ. Short term chemotherapy of tuberculosis. Factors affecting relapse following short term chemotherapy. Bull Int Union Tuberc 1978;53:276-280.
19. Chang KC, et al. A nested case-control study on treatment-related risk factors for early relapse of tuberculosis. Am J Respir Crit Care Med 2004;170:1124-1130.
20. Benator D, et al. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet 2002;360:528-534.
21. Kramnik I, et al. Genetic control of resistance to experimental infection with virulent Mycobacterium tuberculosis. Proc Natl Acad Sci USA 2000;97:8560-8565.
22. Driver ER, et al. Evaluation of a mouse model of necrotic granuloma formation using C3HeB/FeJ mice for testing of drugs against Mycobacterium tuberculosis. Antimicrob Agents Chemother 2012;56:3181-3195.
23. Davis SL, et al. Noninvasive pulmonary (18F)-2-fluoro-deoxy-D-glucose positron emission tomography correlates with bactericidal activity of tuberculosis drug treatment. Antimicrob Agents Chemother 2009;53:4879-4884.
24. Irwin SM, et al. Limited activity of clofazimine as a single drug in a mouse model of tuberculosis exhibiting caseous necrotic granulomas. Antimicrob Agents Chemother 2014;58:4026-4034.
25. Skerry C, et al. Adjunctive TNF inhibition with standard treatment enhances bacterial clearance in a murine model of necrotic TB granulomas. PLoS ONE 2012;7:e39680.
26. Vilaplana C, et al. Ibuprofen therapy resulted in significantly decreased tissue bacillary loads and increased survival in a new murine experimental model of active tuberculosis. J Infect Dis 2013;208:199-202.
27. Marzo E, et al. Damaging role of neutrophilic infiltration in a mouse model of progressive tuberculosis. Tuberculosis 2014;94:55-64.
28. Obregon-Henao A, et al. Gr1(int)CD11b+ myeloid-derived suppressor cells in Mycobacterium tuberculosis infection. PLoS ONE 2013;8:e80669.
29. Lin PL, et al. Tumor necrosis factor neutralization results in disseminated disease in acute and latent Mycobacterium tuberculosis infection with normal granuloma structure in a cynomolgus macaque model. Arthritis Rheum 2010;62:340-350.
30. Lin PL, et al. Radiologic responses in cynomolgous macaques for assessing tuberculosis chemotherapy regimens. Antimicrob Agents Chemother 2013;57:4237-4244.
31. Sharpe SA, et al. Establishment of an aerosol challenge model of tuberculosis in rhesus macaques and an evaluation of endpoints for vaccine testing. Clin Vaccine Immunol 2010;17:1170-1182.
32. Darrah PA, et al. Aerosol vaccination with AERAS-402 elicits robust cellular immune responses in the lungs of rhesus macaques but fails to protect against high-dose Mycobacterium tuberculosis challenge. J Immunol 2014;193:1799-1811.
33. Manabe YC, et al. Different strains of Mycobacterium tuberculosis cause various spectrums of disease in the rabbit model of tuberculosis. Infect Immun 2003;71:6004-6011.
34. Manabe YC, et al. The aerosol rabbit model of TB latency, reactivation and immune reconstitution inflammatory syndrome. Tuberculosis 2008;88:187-196.
35. Subbian S, et al. Spontaneous latency in a rabbit model of pulmonary tuberculosis. Am J Pathol 2012;181:1711-1724.
36. Subbian S, et al. Chronic pulmonary cavitary tuberculosis in rabbits: a failed host immune response. Open Biol 2011;1:110016. doi: 10.1098/rsob.110016.
37. Kjellsson MC, et al. Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions. Antimicrob Agents Chemother 2012;56:446-457.
38. Lin PL, et al. Sterilization of granulomas is common in active and latent tuberculosis despite within-host variability in bacterial killing. Nat Med 2014;20:75-79.
39. Tobin DM, Ramakrishnan L. TB: the Yin and Yang of lipid mediators. Curr Opin Pharmacol 2013;13:641-645.
40. Mayer-Barber KD, et al. Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk. Nature 2014;511:99-103.
41. Behar SM, Divangahi M, Remold HG. Evasion of innate immunity by Mycobacterium tuberculosis: is death an exit strategy? Nat Rev Microbiol 2010;8:668-674.
42. Tobin DM, et al. The lta4h locus modulates susceptibility to mycobacterial infection in zebrafish and humans. Cell 2010;140:717-730.
43. Tobin DM, et al. Host genotype-specific therapies can optimize the inflammatory response to mycobacterial infections. Cell 2012;148:434-446.
44. Lalvani A, Behr MA, Sridhar S. Innate immunity to TB: a druggable balancing act. Cell 2012;148:389-391.
45. Mattila JT, et al. Microenvironments in tuberculous granulomas are delineated by distinct populations of macrophage subsets and expression of nitric oxide synthase and arginase isoforms. J Immunol 2013;191:773-784.
46. Subbian S, et al. Early innate immunity determines outcome of Mycobacterium tuberculosis pulmonary infection in rabbits. Cell Commun Signal 2013;11:60.
47. Palanisamy GS, et al. Clinical strains of Mycobacterium tuberculosis display a wide range of virulence in guinea pigs. Tuberculosis 2009;89:203-209.
48. Reed MB, et al. A glycolipid of hypervirulent tuberculosis strains that inhibits the innate immune response. Nature 2004;431:84-87.
49. Martineau AR, et al. Neutrophil-mediated innate immune resistance to mycobacteria. J Clin Invest 2007;117:1988-1994.
50. Barnes PF, et al. Predictors of short-term prognosis in patients with pulmonary tuberculosis. J Infect Dis 1988;158:366-371.
51. Lowe DM, et al. Neutrophilia independently predicts death in tuberculosis. Eur Respir J 2013;42:1752-1757.
52. Condos R, et al. Local immune responses correlate with presentation and outcome in tuberculosis. Am J Respir Crit Care Med 1998;157(3 Pt 1):729-735.
53. Eum SY, et al. Neutrophils are the predominant infected phagocytic cells in the airways of patients with active pulmonary TB. Chest 2010;137:122-128.
54. Lowe DM, et al. Neutrophils in tuberculosis: friend or foe? Trends Immunol 2012;33:14-25.
55. Corleis B, et al. Escape of Mycobacterium tuberculosis from oxidative killing by neutrophils. Cell Microbiol 2012;14:1109-1121.
56. Kolaczkowska E, Kubes P. Neutrophil recruitment and function in health and inflammation. Nat Rev Immunol 2013;13:159-175.
57. Tsuda Y, et al. Three different neutrophil subsets exhibited in mice with different susceptibilities to infection by methicillin-resistant Staphylococcus aureus. Immunity 2004;21:215-226.
58. Nandi B, Behar SM. Regulation of neutrophils by interferon-gamma limits lung inflammation during tuberculosis infection. J Exp Med 2011;208:2251-2262.
59. Ernst JD. The immunological life cycle of tuberculosis. Nat Rev Immunol 2012;12:581-591.
60. Orme IM. A new unifying theory of the pathogenesis of tuberculosis. Tuberculosis 2014;94:8-14.
61. Ulrichs T, et al. Modified immunohistological staining allows detection of Ziehl-Neelsen-negative Mycobacterium tuberculosis organisms and their precise localization in human tissue. J Pathol 2005;205:633-640.
62. Deb C, et al. A novel in vitro multiple-stress dormancy model for Mycobacterium tuberculosis generates a lipid-loaded, drug-tolerant, dormant pathogen. PLoS ONE 2009;4:e6077.
63. Bhatt A, et al. Deletion of kasB in Mycobacterium tuberculosis causes loss of acid-fastness and subclinical latent tuberculosis in immunocompetent mice. Proc Natl Acad Sci USA 2007;104:5157-5162.
64. Yuan Y, et al. The effect of oxygenated mycolic acid composition on cell wall function and macrophage growth in Mycobacterium tuberculosis. Mol Microbiol 1998;29:1449-1458.
65. Seiler P, et al. Cell-wall alterations as an attribute of Mycobacterium tuberculosis in latent infection. J Infect Dis 2003;188:1326-1331.
66. Ryan GJ, et al. Multiple M. tuberculosis phenotypes in mouse and guinea pig lung tissue revealed by a dual-staining approach. PLoS ONE 2010;5:e11108.
67. Steingart KR, et al. Fluorescence versus conventional sputum smear microscopy for tuberculosis: a systematic review. Lancet Infect Dis 2006;6:570-581.
68. Ryan GJ, Shapiro HM, Lenaerts AJ. Improving acid-fast fluorescent staining for the detection of mycobacteria using a new nucleic acid staining approach. Tuberculosis 2014;94:511-518.
69. Munoz-Elias EJ, et al. Replication dynamics of Mycobacterium tuberculosis in chronically infected mice. Infect Immun 2005;73:546-551.
70. Galagan JE, et al. The Mycobacterium tuberculosis regulatory network and hypoxia. Nature 2013;499:178-183.
71. Wayne LG, Sohaskey CD. Nonreplicating persistence of mycobacterium tuberculosis. Annu Rev Microbiol 2001;55:139-163.
72. Boon C, Dick T. How Mycobacterium tuberculosis goes to sleep: the dormancy survival regulator DosR a decade later. Future Microbiol 2012;7:513-518.
73. Tsai MC, et al. Characterization of the tuberculous granuloma in murine and human lungs: cellular composition and relative tissue oxygen tension. Cell Microbiol 2006;8:218-232.
74. Via LE, et al. Tuberculous granulomas are hypoxic in guinea pigs, rabbits, and non-human primates. Infect Immun 2008;76:2333-2340.
75. Aly S, et al. Oxygen status of lung granulomas in Mycobacterium tuberculosis-infected mice. J Pathol 2006;210:298-305.
76. Lenaerts AJ, et al. Location of persisting mycobacteria in a Guinea pig model of tuberculosis revealed by r207910. Antimicrob Agents Chemother 2007;51:3338-3345.
77. Harper J, et al. Mouse model of necrotic tuberculosis granulomas develops hypoxic lesions. J Infect Dis 2012;205:595-602.
78. Voskuil MI, et al. Inhibition of respiration by nitric oxide induces a Mycobacterium tuberculosis dormancy program. J Exp Med 2003;198:705-713.
79. Wayne LG, Hayes LG. An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect Immun 1996;64:2062-2069.
80. Raleigh JA, et al. Hypoxia and vascular endothelial growth factor expression in human squamous cell carcinomas using pimonidazole as a hypoxia marker. Cancer Res 1998;58:3765-3768.
81. Koller F, Leuthardt F. Nekrose und autolyse beitrag zur kenntnis der dystrophischen verkalkung. Klin Wochenschr 1934;43:1527-1529.
82. Watanabe S, et al. Fumarate reductase activity maintains an energized membrane in anaerobic Mycobacterium tuberculosis. PLoS Pathog 2011;7:e1002287.
83. Kim MJ, et al. Caseation of human tuberculosis granulomas correlates with elevated host lipid metabolism. EMBO Mol Med 2010;2:258-274.
84. Deb C, et al. A novel lipase belonging to the hormone-sensitive lipase family induced under starvation to utilize stored triacylglycerol in Mycobacterium tuberculosis. J Biol Chem 2006;281:3866-3875.
85. Raju B, et al. Gene expression profiles of bronchoalveolar cells in pulmonary TB. Tuberculosis 2008;88:39-51.
86. Pandey AK, Sassetti CM. Mycobacterial persistence requires the utilization of host cholesterol. Proc Natl Acad Sci USA 2008;105:4376-4380.
87. Dhouib R, et al. Watching intracellular lipolysis in mycobacteria using time lapse fluorescence microscopy. Biochim Biophys Acta 2011;1811:234-241.
88. Daniel J, et al. Mycobacterium tuberculosis uses host triacylglycerol to accumulate lipid droplets and acquires a dormancy-like phenotype in lipid-loaded macrophages. PLoS Pathog 2011;7:e1002093.
89. Garton NJ, et al. Cytological and transcript analyses reveal fat and lazy persister-like bacilli in tuberculous sputum. PLoS Med 2008;5:e75.
90. Caire-Brandli I, et al. Reversible lipid accumulation and associated division arrest of Mycobacterium avium in lipoprotein-induced foamy macrophages may resemble key events during latency and reactivation of tuberculosis. Infect Immun 2014;82:476-490.
91. Simeone R, et al. Phagosomal rupture by Mycobacterium tuberculosis results in toxicity and host cell death. PLoS Pathog 2012;8:e1002507.
92. Vergne I, et al. Mechanism of phagolysosome biogenesis block by viable Mycobacterium tuberculosis. Proc Natl Acad Sci USA 2005;102:4033-4038.
93. Cappelli G, et al. Profiling of Mycobacterium tuberculosis gene expression during human macrophage infection: upregulation of the alternative sigma factor G, a group of transcriptional regulators, and proteins with unknown function. Res Microbiol 2006;157:445-455.
94. Schnappinger D, et al. Transcriptional adaptation of Mycobacterium tuberculosis within macrophages: insights into the phagosomal environment. J Exp Med 2003;198:693-704.
95. Tailleux L, et al. Probing host pathogen cross-talk by transcriptional profiling of both Mycobacterium tuberculosis and infected human dendritic cells and macrophages. PLoS ONE 2008;3:e1403.
96. Talaat AM, et al. The temporal expression profile of Mycobacterium tuberculosis infection in mice. Proc Natl Acad Sci USA 2004;101:4602-4607.
97. Bishai W. Lipid lunch for persistent pathogen. Nature 2000;406:683-685.
98. McKinney JD, et al. Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. Nature 2000;406:735-738.
99. Munoz-Elias EJ, McKinney JD. Mycobacterium tuberculosis isocitrate lyases 1 and 2 are jointly required for in vivo growth and virulence. Nat Med 2005;11:638-644.
100. Marrero J, et al. Gluconeogenic carbon flow of tricarboxylic acid cycle intermediates is critical for Mycobacterium tuberculosis to establish and maintain infection. Proc Natl Acad Sci USA 2010;107:9819-9824.
101. Fritz C, et al. Dependence of Mycobacterium bovis BCG on anaerobic nitrate reductase for persistence is tissue specific. Infect Immun 2002;70:286-291.
102. Hutter B, Dick T. Molecular genetic characterisation of whiB3, a mycobacterial homologue of a Streptomyces sporulation factor. Res Microbiol 1999;150:295-301.
103. Weber I, et al. Anaerobic nitrate reductase (narGHJI) activity of Mycobacterium bovis BCG in vitro and its contribution to virulence in immunodeficient mice. Mol Microbiol 2000;35:1017-1025.
104. Kaplan G, et al. Mycobacterium tuberculosis growth at the cavity surface: a microenvironment with failed immunity. Infect Immun 2003;71:7099-7108.
105. Weiss C, Tabachnick J, Cohen HP. Mechanism of softening of tubercles. III. Hydrolysis of protein and nucleic acid during anaerobic autolysis of normal and tuberculous lung tissue in vitro. AMA Arch Pathol 1954;57:179-193.
106. Rojas-Espinosa O, et al. The role of cathepsin D in the pathogenesis of tuberculosis. A histochemical study employing unlabeled antibodies and the peroxidase-antiperoxidase complex. Am J Pathol 1974;74:1-17.
107. Yamamura Y, Ogawa Y, Maeda H. Prevention of tuberculous cavity formation by desensitization with tuberculin-active peptide. Am Rev Respir Dis 1974;109:594-601.
108. Luna B, et al. In vivo prediction of tuberculosis cavity formation in rabbits. J Infect Dis 2014;211:481-485.
109. Langermans JA, et al. Divergent effect of bacillus Calmette-Guerin (BCG) vaccination on Mycobacterium tuberculosis infection in highly related macaque species: implications for primate models in tuberculosis vaccine research. Proc Natl Acad Sci USA 2001;98:11497-11502.
110. Ulrichs T, Kaufmann SH. New insights into the function of granulomas in human tuberculosis. J Pathol 2006;208:261-269.
111. Leong FJ, et al. Pathology of tuberculosis in the human lung. In: Leong FJ, Dartois V, Dick T eds. A Color Atlas of Comparative Pathology of Pulmonary Tuberculosis. CRC Press, 2011:53-81.
112. Aly S, et al. Interferon-gamma-dependent mechanisms of mycobacteria-induced pulmonary immunopathology: the role of angiostasis and CXCR3-targeted chemokines for granuloma necrosis. J Pathol 2007;212:295-305.
113. Van de Velde S, et al. Contrasting effects of human THP-1 cell differentiation on levofloxacin and moxifloxacin intracellular accumulation and activity against Staphylococcus aureus and Listeria monocytogenes. J Antimicrob Chemother 2008;62:518-521.
114. Rey-Jurado E, et al. Activity and interactions of levofloxacin, linezolid, ethambutol and amikacin in three-drug combinations against Mycobacterium tuberculosis isolates in a human macrophage model. Int J Antimicrob Agents 2013;42:524-530.
115. Baik J, et al. Multiscale distribution and bioaccumulation analysis of clofazimine reveals a massive immune system-mediated xenobiotic sequestration response. Antimicrob Agents Chemother 2013;57:1218-1230.
116. Prideaux B, et al. High-sensitivity MALDI-MRM-MS imaging of moxifloxacin distribution in tuberculosis-infected rabbit lungs and granulomatous lesions. Anal Chem 2011;83:2112-2118.
117. Prideaux B, Stoeckli M. Mass spectrometry imaging for drug distribution studies. J Prot 2012;75:4999-5013.
118. Skerry C, et al. Simvastatin increases the in vivo activity of the first-line tuberculosis regimen. J Antimicrob Chemother 2014;69:2453-2457.
119. Subbian S, et al. Phosphodiesterase-4 inhibition combined with isoniazid treatment of rabbits with pulmonary tuberculosis reduces macrophage activation and lung pathology. Am J Pathol 2011;179:289-301.
120. Salamon H, et al. Cutting edge: vitamin D regulates lipid metabolism in Mycobacterium tuberculosis infection. J Immunol 2014;193:30-34.
121. Corson MA. Darapladib: an emerging therapy for atherosclerosis. Ther Adv Cardiovasc Dis 2010;4:241-248.
122. Serruys PW, et al. Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque. Circulation 2008;118:1172-1182.
123. Ridker PM, Luscher TF. Anti-inflammatory therapies for cardiovascular disease. Eur Heart J 2014;35:1782-1791.
124. Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis 1999;3(10 Suppl 2):S231-S279.
125. Mitchison DA. The action of antituberculosis drugs in short-course chemotherapy. Tubercle 1985;66:219-225.
126. Yano T, et al. Reduction of clofazimine by mycobacterial type 2 NADH:quinone oxidoreductase: a pathway for the generation of bactericidal levels of reactive oxygen species. J Biol Chem 2011;286:10276-10287.
127. Wallis RS, et al. Whole blood bactericidal activity during treatment of pulmonary tuberculosis. J Infect Dis 2003;187:270-278.
128. Zhu T, et al. Population pharmacokinetic/pharmacodynamic analysis of the bactericidal activities of sutezolid (PNU-100480) and its major metabolite against intracellular mycobacterium tuberculosis in ex vivo whole-blood cultures of patients with pulmonary tuberculosis. Antimicrob Agents Chemother 2014;58:3306-3311.
129. Dhillon J, et al. Metronidazole has no antibacterial effect in Cornell model murine tuberculosis. Int J Tuberc Lung Dis 1998;2:736-742.
130. Lin PL, et al. Metronidazole prevents reactivation of latent Mycobacterium tuberculosis infection in macaques. Proc Natl Acad Sci USA 2012;109:14188-14193.
131. Hoff DR, et al. Metronidazole lacks antibacterial activity in guinea pigs infected with Mycobacterium tuberculosis. Antimicrob Agents Chemother 2008;52:4137-4140.
132. Carroll MW, et al. Efficacy and safety of metronidazole for pulmonary multidrug-resistant tuberculosis. Antimicrob Agents Chemother 2013;57:3903-3909.
133. Ramakrishnan L. Looking within the zebrafish to understand the tuberculous granuloma. Adv Exp Med Biol 2013;783:251-266.
134. Swaim LE, et al. Mycobacterium marinum infection of adult zebrafish causes caseating granulomatous tuberculosis and is moderated by adaptive immunity. Infect Immun 2006;74:6108-6117.
135. Basaraba RJ. Experimental tuberculosis: the role of comparative pathology in the discovery of improved tuberculosis treatment strategies. Tuberculosis 2008;88(Suppl 1):S35-S47.
136. Rosenthal IM, et al. Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis. Antimicrob Agents Chemother 2012;56:4331-4340.
137. Singhal A, et al. BCG induces protection against Mycobacterium tuberculosis infection in the Wistar rat model. PLoS ONE 2011;6:e28082.
138. Palanisamy GS, et al. Disseminated disease severity as a measure of virulence of Mycobacterium tuberculosis in the guinea pig model. Tuberculosis 2008;88:295-306.
139. Gonzalez-Juarrero M, et al. Experimental aerosol Mycobacterium bovis model of infection in goats. Tuberculosis 2013;93:558-564.
140. Sanchez J, et al. Microscopical and immunological features of tuberculoid granulomata and cavitary pulmonary tuberculosis in naturally infected goats. J Comp Pathol 2011;145:107-117.
141. Gil O, et al. Granuloma encapsulation is a key factor for containing tuberculosis infection in minipigs. PLoS ONE 2010;5:e10030.
142. Kaushal D, et al. The non-human primate model of tuberculosis. J Med Primatol 2012;41:191-201.
143. Lin PL, et al. Early events in Mycobacterium tuberculosis infection in cynomolgus macaques. Infect Immun 2006;74:3790-3803.